[Skip to Content]
[Skip to Content Landing]
June 1966

Fibrinolysis and Proteolysis in Patients With Lymphoma

Author Affiliations


From the Clotting Mechanisms Section, Memorial Sloan-Kettering Cancer Center, New York. Dr. Girolami is presently at the Institute of Semeiotica Medica, University of Padua Medical School, Padua, Italy.

Arch Intern Med. 1966;117(6):778-783. doi:10.1001/archinte.1966.03870120042009

INCREASED fibrinolytic activity has been described in several malignant diseases. Acute and chronic leukemia 1-9 and metastatic carcinoma of the prostate 10-14 are the conditions most commonly reported to be associated with marked fibrinolysis. Hyperfibrinolysis has also been observed in polycythemia vera,15 multiple myeloma,14,16 carcinoma of the pancreas,17 metastatic carcinoma of the stomach,18 and neuroblastoma.19

The behavior of blood fibrinolysis in lymphomas is still poorly known. Increased in vitro fibrinogenolysis has been demonstrated in the plasma of ten out of 11 patients with Hodgkin's disease.20 Others 4,18,21 found the fibrinolytic activity to be practically normal in patients with lymphomas showing only occasional minor inhibition 21 or acceleration.18

The present investigation reports our observations of fibrinolysis and proteolysis in a series of 125 patients with Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma.

Materials and Methods  Of the 125 patients, 58 had Hodgkin's disease, 33 had lymphosarcoma, and 34 had reticulum cell

First Page Preview View Large
First page PDF preview
First page PDF preview